• Idebenone - analysis
  • Idebenone powder - Zion Pharma

Idebenone powder

8,6035,00

Idebenone is a man-made nootropic. It is similar to coenzyme Q10.

Studies suggest Idebenone may diminish nerve cell damage due to ischaemia, correct neurotransmitter defects and/or cerebral metabolism and facilitate memory and learning.

SKU: idebenone-powder

ACTIVE INGREDIENT: Idebenone >98%

OTHER NAMES: Noben, Catena, Raxone, Sovrima, 2,3-dimethoxy-5-methyl-6-(10′-hydroxydecyl)-1,4-benzoquinone

CAS NUMBER: 58186-27-9

ATC CODE: N06BX13

FORMULA: C19H30O5

ITEM TYPE: Powder

QUANTITY PER PACK: 1 g to 10 g

SERVINGS PER PACK: not specified

SUGGESTED USE: up to 900 mg per day.

STORAGE: Store in a cool and dry place. Keep away from direct sunlight and heat.

WARNING: Keep out of reach of children. Do not take this or any other supplement if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions, and/or taking prescription drugs or over the counter medications.

DISCLAIMER: Always consult with a qualified health physician before taking any new dietary supplement. This product is not intended to diagnose, treat, cure, or prevent any diseases.

SCOOPS: This product includes a measuring scoop.

The product is not intended for human use. For laboratory use only.

Summary of product characteristics – Raxone 150 mg film-coated tablets – https://www.ema.europa.eu/en/documents/product-information/raxone-epar-product-information_en.pdf

Idebenone as nootropic

Idebenone is a benzoquinone compound which has been investigated in elderly patients with dementia. Its precise mechanism(s) of action remains unknown, but in vitro and in vivo studies suggest the drug may diminish nerve cell damage due to ischaemia, correct neurotransmitter defects and/or cerebral metabolism and facilitate memory and learning. In the small number of studies available for evaluation, idebenone was generally superior to placebo and comparable with bifemelane, oxiracetam and nebracetam on the basis of a number of objective and subjective tests and rating scales in patients with mild to moderate cognitive decline

How does it work?

Idebenone seems to have antioxidant activity, and appears to protect a wide variety of cells from oxidative damage.

Clinical trial results indicate that patients with mild dementia seem more likely to respond than those with greater functional decline. The degree of benefit conferred by idebenone is often difficult to determine, but in those who respond, improvement is generally mild to moderate.

Therapy with idebenone appears well tolerated for up to 2 years, and no changes in vital signs or laboratory values have been seen in clinical trials. In view of the lack of a proven agent to limit or halt the progression of dementia in the elderly, idebenone may warrant consideration in patients with mild cognitive dysfunction on the basis of preliminary evidence of predominantly mild improvement of functional status in some patients and good tolerability. However, further well designed studies, including comparisons with newer and commonly used agents, such as tacrine, are required to better define the role of idebenone in this complex area of treatment.

Source: https://pubmed.ncbi.nlm.nih.gov/7981485/

Effect of idebenone on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptor was evaluated using Xenopus oocytes injected with RNAs encoding mouse alpha 1 and alpha 2 AMPA receptors. Concanavalin A augmented current responses of the RNA-injected oocytes to glutamate, kainate, and AMPA and these responses were further potentiated by 100 microM idebenone. The minimum concentration of idebenone that gave a significant potentiation was 10 microM for glutamate. These results suggest that idebenone acts on AMPA-selective glutamate receptor channels composed of alpha 1 and alpha 2 subunits.

Source: https://pubmed.ncbi.nlm.nih.gov/7511959/

Dosage (for Noben)

30 mg 2-3 times a day after meals, the last intake is no later than 5 pm. The duration of the treatment is 1.5–2 months. Depending on the severity of the symptoms 2-3 courses per year are administered. Idebenone is fat-soluble. It should be taken with a meal.